Welcome to our dedicated page for Chemomab Therapeutics Ltd. American Depositary Share news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics Ltd. American Depositary Share stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the development of innovative therapeutics to treat fibro-inflammatory diseases with significant unmet medical needs. The company's proprietary platform centers on CM-101, a first-in-class monoclonal antibody that targets the protein CCL24, a key regulator of inflammatory and fibrotic pathways in several severe diseases.
CM-101 has demonstrated potential in disrupting the underlying biology of fibrosis through a novel mechanism of action. The company is actively advancing CM-101 through multiple Phase 2 clinical trials aimed at treating rare and life-threatening conditions such as primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc). In recognition of its innovative approach, CM-101 has been granted Orphan Drug designation in both the U.S. and the European Union, and it recently received Fast Track designation from the FDA for PSC treatment.
Chemomab has reported encouraging preliminary results from these trials, which indicate that CM-101 is safe and effective in interfering with fibrotic and inflammatory pathways. The company has secured robust intellectual property protections for CM-101, with patents granted or pending in major territories worldwide, ensuring proprietary rights for the treatment of multiple indications until at least 2038.
Recent highlights from Chemomab include:
- Completion of patient enrollment in the Phase 2 PSC trial, with topline data expected mid-2024.
- Granting of new patents in Brazil, Israel, and Europe that further protect the use of CM-101 in treating liver diseases and other conditions.
- Publication of peer-reviewed studies validating the role of CCL24 in driving PSC and SSc pathologies, and the potential of CM-101 as a therapeutic intervention.
- Presentations at major scientific conferences including EASL 2024 and the Gordon Research Conference, showcasing novel translational assays and proteomic profiling studies that support the efficacy of CM-101.
As Chemomab continues to advance its clinical programs and expand its scientific understanding of fibro-inflammatory diseases, it remains committed to addressing the urgent need for effective treatments in these challenging medical areas.
Rhea-AI Summary
Chemomab Therapeutics announced a new peer-reviewed publication confirming the role of its CCL24 protein target in systemic sclerosis. The study, conducted on over 200 patients, showed a strong association between high CCL24 levels and disease severity, mortality, and various clinical manifestations of systemic sclerosis. The findings support the potential of Chemomab's CCL24-neutralizing antibody, CM-101, as a promising therapeutic option for systemic sclerosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.64%
Tags
-
Rhea-AI Summary
Chemomab Therapeutics announces a key opinion leader event on primary sclerosing cholangitis, featuring experts discussing disease management and clinical development. The event will highlight the urgent need for new PSC treatments and the CM-101 Phase 2 clinical trial with topline results expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
-
Rhea-AI Summary
Chemomab Therapeutics (Nasdaq: CMMB) receives a new patent from the European Patent Office for CM-101, a monoclonal antibody targeting CCL24 for treating liver diseases, including Primary Sclerosing Cholangitis. The patent extends protections in key European markets and complements existing patents in the U.S., Europe, Israel, and other regions. CM-101 is currently in Phase 2 SPRING trial for PSC, with promising results expected by mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
Rhea-AI Summary
Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) announced accelerated Phase 2 CM-101 PSC trial timeline with topline data expected in mid-2024, extended cash runway, and achievements positioning the company for potential transformation in 2024. The company aims to advance CM-101 for fibro-inflammatory diseases and achieve clinical proof-of-concept.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.68%
Tags
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. CEO, Dr. Adi Mor, will present at the Leerink Partners Global Biopharma Conference on March 12, 2024, in Miami. The presentation aims to showcase the company's innovative therapeutics for fibro-inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. (CMMB) completes patient enrollment for CM-101 Phase 2 trial for treating Primary Sclerosing Cholangitis, with topline data expected in mid-2024. New patents granted in Brazil and Israel enhance protection for CM-101 in fibrotic liver diseases, including PSC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
Rhea-AI Summary
Chemomab Therapeutics Ltd. (CMMB) will release its fourth quarter and full year 2023 financial results and provide a business update on March 7, 2024. The company focuses on developing therapeutics for fibro-inflammatory diseases with high unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced that CEO Dr. Adi Mor and other senior management will participate in two upcoming investor conferences. Dr. Mor will deliver a corporate presentation and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference and the Leerink Partners Global Biopharma Conference. The Oppenheimer Conference presentation will be webcast live and available on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.49%
Tags
-
Rhea-AI Summary
Chemomab Therapeutics Ltd. announced the publication of proteomic analyses that demonstrate the unique role of the soluble protein CCL24 in driving pathologies associated with the rare fibrotic liver disease primary sclerosing cholangitis (PSC). The company's first-in-class CCL24-neutralizing antibody CM-101 has the potential to interrupt these destructive processes. The Phase 2 PSC trial for CM-101 has completed patient enrollment, with topline data targeted for midyear 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
Rhea-AI Summary
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced the early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis (PSC). The company expects to report topline data from the PSC clinical trial by midyear 2024, rather than in the second half of 2024 as previously projected. CM-101 is a first-in-class monoclonal antibody with dual anti-inflammatory and anti-fibrotic activity, and it has Orphan Drug designation for PSC in the U.S. and the European Union (EU), as well as Fast Track designation by the U.S. Food & Drug Administration (FDA).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
FAQ
What is the current stock price of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
The current stock price of Chemomab Therapeutics Ltd. American Depositary Share (CMMB) is $2.13 as of January 3, 2025.
What is the market cap of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
The market cap of Chemomab Therapeutics Ltd. American Depositary Share (CMMB) is approximately 41.2M.
What is Chemomab Therapeutics Ltd.?
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company that focuses on developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs.
What is CM-101?
CM-101 is a first-in-class monoclonal antibody developed by Chemomab that targets the protein CCL24 to disrupt inflammatory and fibrotic pathways in severe diseases.
What diseases is CM-101 being tested for?
CM-101 is currently in Phase 2 clinical trials for primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc).
Has CM-101 received any special designations from regulatory authorities?
Yes, CM-101 has been granted Orphan Drug designation in the U.S. and the European Union, and it recently received Fast Track designation from the FDA for the treatment of PSC.
When are the results from the Phase 2 PSC trial expected?
The topline results from the Phase 2 trial for primary sclerosing cholangitis (PSC) are expected to be released by mid-2024.
What recent achievements has Chemomab announced?
Recent achievements include the completion of patient enrollment in the Phase 2 PSC trial, new patents granted in Brazil, Israel, and Europe, and positive findings published in peer-reviewed journals.
What makes CM-101 unique?
CM-101 targets the soluble protein CCL24, which plays a pivotal role in fibrosis and inflammation. Its dual mechanism of action makes it a novel therapeutic candidate for fibro-inflammatory diseases.
What is the significance of the new patents granted to Chemomab?
The new patents strengthen the intellectual property protections for CM-101, covering its use in treating liver diseases and other conditions, and extending proprietary rights until 2038.
Where has Chemomab presented its research?
Chemomab has presented its research at major scientific conferences, including EASL 2024 and the Gordon Research Conference, where it showcased translational assays and proteomic profiling studies.
How does CM-101 work?
CM-101 works by neutralizing CCL24, which disrupts the inflammatory and fibrotic pathways central to several fibro-inflammatory diseases, thereby offering potential therapeutic benefits.
Chemomab Therapeutics Ltd. American Depositary Share
Nasdaq:CMMB
CMMB Rankings
CMMB Stock Data
41.20M
14.12M
11.29%
27.99%
0.86%
Biotechnology
Pharmaceutical Preparations
United States of America
TEL AVIV